The role of Janus kinase inhibitors in the treatment of juvenile idiopathic arthritis
Ugeskrift for Læger · 2025
DOI: 10.61409/v09240622 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ugeskrift for Læger, 2025. Verfasst von Rasmus Saul und 2 weiteren Autor:innen. Beteiligte Einrichtung: Børn og Unge, Aarhus Universitetshospital. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Janus Kinase Inhibitors, Antirheumatic Agents. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Juvenile idiopathic arthritis (JIA) presents ongoing treatment challenges despite advances in treatment over the last few years. This review presents that recent studies highlight the potential of Janus kinase inhibitors (JAKi) to significantly reduce disease activity. However, concerns about long-term safety, including cardiovascular risks and malignancy, underscore the need for more research. While JAKi offers a promising therapeutic avenue in pediatric rheumatology, the long-term safety profile requires further investigation to assert its place in standard treatment guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Børn og Unge, Aarhus Universitetshospital.
- Institut for Klinisk Medicin, Aarhus Universitet.
Zitieren
APA
Saul, R., Herlin, T., & Glerup, M. (2025). The role of Janus kinase inhibitors in the treatment of juvenile idiopathic arthritis. Ugeskrift for Læger. https://doi.org/10.61409/v09240622
Vancouver
Saul R, Herlin T, Glerup M. The role of Janus kinase inhibitors in the treatment of juvenile idiopathic arthritis. Ugeskrift for Læger. 2025. doi:10.61409/v09240622
BibTeX
@article{Saul2025,
author = {Saul, Rasmus and Herlin, Troels and Glerup, Mia},
title = {The role of Janus kinase inhibitors in the treatment of juvenile idiopathic arthritis},
journal = {Ugeskrift for Læger},
year = {2025},
doi = {10.61409/v09240622}
}
EUVIMED